off treatments or to develop resistance or re-establish itself via cancer stem cells," said Donald L. Durden
, MD, PhD, SignalRx President and Chief Executive Officer. "We are among a select group of cancer researchers who are actively developing anticancer drugs with dual inhibitory properties including PI3K/MEK, PI3K/BRAF, PI3K/HDAC, PI3K/PARP, and PI3K/BET bromodomain setting the stage for the most efficacious smart combination anticancer treatments based on evolving cancer biology and personalized oncology paradigms. In addition, these dual inhibitory drugs solve the problem of early stage clinical trial evaluation of multiple combinations by consolidating at least two of the combination partners into one drug. Moreover, one molecule hitting two targets in the same cell is the only way to ensure that desired simultaneous blockage of both signaling pathways is achieved in vivo
because two separate drugs will always suffer from differing cell penetration, metabolism, pharmacokinetics, etc., which promotes tumor cell resistance by diminishing the time and likelihood that useful dual blockage is achieved."
Additional information about these compounds was recently published in the Journal of Medicinal Chemistry (February 14th 2013 issue, volume 56, pages 1922-1939).
About SignalRx Pharmaceuticals Inc.
SignalRx is a privately held corporation developing small molecule inhibitors of key signaling pathways used by cancer and cancer stem cells to evade treatments. Such key signaling pathways include major cell survival mechanisms, epigenetic regulation processes, and DNA repair actions encompassing critical targets such as PI3K, MEK, BRAF, Wnt, HDAC, DNMT, BET bromodomains, and PARP. SignalRx is leveraging its expertise in PI3K pathway inhibition to be the leader in developing single molecule therapeutics that selectively inhibi
Page: 1 2 3 Related biology technology :1
|SOURCE SignalRx Pharmaceuticals Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting2
. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV21979443
. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)4
. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 20115
. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie6
. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck7
. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts8
. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™9
. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference10
. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer11
. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference